NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Feb. 17, 2005--Acacia Research Corporation (NASDAQ:CBMX) (NASDAQ:ACTG) announced today that its CombiMatrix group has moved KM-668, the lead compound in its KM family of therapeutics, into pre-clinical development and animal testing. The KM family of compounds is part of CombiMatrix’s new internal program to develop therapeutics for exposure to terror weapons. As a subset of that program, KM-668 is designed as a treatment for exposure to radiological weapons.
